2. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., Wein A. The standardisation of terminology of lower urinary tract function: Report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn. 2002;21:167–178. Doi: 10.1016/s0090-4295(02)02243-4.

3. D’Ancona C., Haylen B., Oelke M., Abranches-Monteiro L., Arnold E., Goldman H., Hamid R., Homma Y., Marcelissen T., Rademakers K., Schizas A., Singla A., Soto I., Tse V., de Wachter S., Herschorn S. The International Continence Society (ICS) report on the terminology for adult male lower urinary tract and pelvic floor symptoms and dysfunction. Neurourol Urodyn. 2019;38:433. Doi: 10.1002/nau.23897.

4. Nitti V.W., Rovner E.S., Bavendam T. Response to fesoterodine in patients with an overactive bladder and urgency urinary incontinence is independent of the urodynamic finding of detrusor overactivity. BJU Int. 2010;105:1268. Doi: 10.1111/j.1464-410X.2009.09037.x.

5. Hess R., Huang A.J., Richter H.E., Ghetti C.C., Sung V.W., Barrett-Connor E., Gregory W.T., Pinkerton J.V., Bradley C.S., Kraus S.R., Rogers R.G., Subak L.L., Johnson K.C., Arya L.A., Schembri M., Brown J.S. Long-term efficacy and safety of questionnaire-based initiation of urgency urinary incontinence treatment. Am J Obstet Gynecol. 2013 Sep;209(3):244.e1-9. Doi: 10.1016/j.ajog.2013.05.008.

6. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thüroff J., Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int. 2001 Jun;87(9):760-6. BJU Int. 2001 Nov;88(7):807. Doi: 10.1046/j.1464-410x.2001.02228.x.

7. Stewart W., Van Rooyen J., Cundiff G., Abrams P., Herzog A.R., Corey R., Hunt T.L., Wein A.J. Prevalence and burden of overactive bladder in the United States. World J. Urol. 2003;20:327–336. Doi: 0.1007/s00345-002-0301-4.

8. Irwin D.E., Milsom I., Hunskaar S., Reilly K., Kopp Z., Herschorn S., Coyne K., Kelleher C., Hampel C., Artibani W., Abrams P. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 2006 Dec;50(6):1306-14; discussion 1314-5. Epub 2006 Oct 2. Doi: 10.1016/j.eururo.2006.09.019.

9. Coyne K.S., Sexton C.C., Thompson C.L., Milsom I., Irwin D., Kopp Z.S., Chapple C.R., Kaplan S., Tubaro A., Aiyer L.P., Wein A.J. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009Aug;104(3):352–360.Doi: 10.1111/j.1464-410X.2009.08427.x.

10. Трапезникова М.Ф., Дутов В.В., Бычкова Н.В., Головченко К.В. Эпидемиология и лечение гиперактивного мочевого пузыря. Альманах клинической медицины. 2005;8–1:307–310.

11. Kogan M.I., Zachoval R., Ozyurt C., Schäfer T., Christensen N. Epidemiology and impact of urinary incontinence, overactive bladder, and other lower urinary tract symptoms: results of the EPIC survey in Russia, Czech Republic, and Turkey. Curr. Med. Res. Opin. 2014 Oct;30(10):2119–2130. Doi: 10.1185/03007995.2014.934794.

12. Nygaard I.E., Lemke J.H. Urinary incontinence in rural older women: Prevalence, incidence and remission. J. Am. Geriatr. Soc. 1996;44:1049–1054. Doi: 10.1111/j.1532-5415.1996.tb02936.x.

13. Björnsdóttir L.T., Geirsson R.T., Jónsson P.V. Urinary incontinence and urinary tract infections in octogenarian women. Acta Obstet. Gynecol. Scand. 1998;77:105–109. Doi: 10.1034/j.1600-0412.1998.770122.x.

14. Samuelsson E., Victor A., Tibblin G. A population study of urinary incontinence and nocturia among women aged 20-59 years. Acta Obstet. Gynecol. Scand. 1997;76:74–80. Doi: 10.3109/00016349709047789.

15. Gadzhieva Z.K. The functional state of the lower urinary tract and drug correction of urinary disorders in women in the menopausal period: abstract of the dissertation of the candidate of medical sciences. M., 2001. 189 p. Russian (Гаджиева З.К. Функциональное состояние нижних мочевых путей и медикаментозная коррекция расстройств мочеиспускания у женщин в климактерическом периоде: автореферат дис. кан. мед. наук. М., 2001. 189 с.).

16. Kizilov Yu.B. Features of diagnosis and treatment of various urinary disorders in residents of the Republic of Dagestan.: abstract of the dissertation of the candidate of medical sciences. M.: 2017. 185 p. Russian (Казилов Ю.Б. Особенности диагностики и лечения различных нарушений мочеиспускания у жителей республики Дагестан.: автореферат дис. кан. мед. наук. М.: 2017. 185 с.).

17. Simeonova Z., Milsom I, Kullendorff A.M., Molander U., Bengtsson C. The prevalence of urinary incontinence and its influence on the quality of life in women from an urban Swedish population. Acta Obstet. Gynecol. Scand. 1999;78:546–551.

18. O’Brien J., Austin M., Sethi P., O’Boyle P. Urinary incontinence: Prevalence, need for treatment, and effectiveness of intervention by nurse. BMJ 1991;303:1308–1312. Doi: 10.1136/bmj.303.6813.1308.

19. Umlauf M.G., Sherman S.M. Symptoms of urinary incontinence among older community-dwelling men. J. Wound Ostomy Continence Nurs. 1996 Nov;23(6):314–321. Doi: 10.1016/s1071-5754(96)90052-2.

20. https://rosstat.gov.ru/free_doc/new_site/population/demo/progn7.htm

21. Nakagawa H., Niu K., Hozawa A., Ikeda Y., Kaiho Y., Ohmori-Matsuda K., Nakaya N., Kuriyama S,. Ebihara S., Nagatomi R., Tsuji I., Arai Y. Impact of nocturia on bone fracture and mortality in older individuals: a Japanese longitudinal cohort study. J. Urol. 2010 Oct;184(4):1413–1418. Doi: 10.1016/j.juro.2010.05.093.

22. Jeffcoate T.N., Francis W.J. Urgency Incontinence in the Female. Am. J. Obstet. Gynecol. 1966;94(5):604–618. Doi: 10.1016/0002-9378(66)90395-4.

23. Fantl J.A., Wyman J.F., McClish D.K., Harkins S.W., Elswick R.K., Taylor J.R., Hadley EC. Efficacy of Bladder Training in Older Women with Urinary Incontinence. JAMA. 1991;265(5):609–613.

24. O’Donnel P.D. Biofeedback Therapy. In: Raz S. (ed.). Female Urology. 2nd ed., Philadelphia: W.B. Saunders; 1996, рр. 253–261. Doi: 10.1016/0090-4295(91)80104-f.

25. Hay-Smith E.J., Bo K., Berghmans L.C., Hendriks H.J., de Bie R.A., van Waalwijk van Doorn E.S. WITHDRAWN: Pelvic Floor Muscle Training for Urinary Incontinence in Women. Cochrane Database Syst. Rev. 2007;(1). Doi: 10.1002/14651858.CD001407.

26. Ostaszkiewicz J., Johnston L., Roe B. Habit retraining for the management of urinary incontinence in adults. Cochrane Database Syst. Rev. 2004. 2010. Doi: 10.1002/14651858.CD002801.pub2.

27. NICE Guidance – Urinary incontinence and pelvic organ prolapse in women: management. BJU International. 2019;123:777. Doi: 10.1111/bju.14763.

28. Imamura M., Abrams P., Bain C., Buckley B., Cardozo L., Cody J., Cook J., Eustice S., Glazener C., Grant A., Hay-Smith J., Hislop J,. Jenkinson D., Kilonzo M., Nabi G., N’Dow J., Pickard R., Ternent L., Wallace S., Wardle J., Zhu S., Vale L. Systematic review and economic modelling of the effectiveness and cost-effectiveness of non-surgical treatments for women with stress urinary incontinence. Health Technol Assess. 2010 Aug;14(40):1–188, iii-iv. Doi: 10.3310/hta14400.

29. Shamliyan T., Wyman J., Kane R.L. Nonsurgical Treatments for Urinary Incontinence in Adult Women: Diagnosis and Comparative Effectiveness. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Apr.

30. Rai B.P., et al. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst. Rev. 2012. 12. doi:10.1002/14651858.CD003193.pub4.

31. Abrams P., Andersson K. E., Birder L., Brubaker L., Cardozo L., Chapple C., Drake M. Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourology and Urodynamics. 2010;29(1), 213–240. Doi: 10.1002/nau.20870.

32. Huang Z., Wu S., Yu T., Hu A. Efficacy of telemedicine for urinary incontinence in women: a systematic review and meta-analysis of randomized controlled trials. Int. Urogynecol J. 2020;31:1507. Doi: 10.1007/s00192-020-04340-2.

33. Burkhard F.C., Bosch J.L.H.R., Cruz F., Lemack G.E., Nambiar A.K., Thiruchelvam N., Tubaro A. EAU Guidelines on Assessment and Nonsurgical Management of Urinary Incontinence. Eur. Urol. 2018 Apr;73(4):596–609. Doi: 10.1016/j.eururo.2017.12.031.

34. Gray S.L., Anderson M.L., Dublin S., Hanlon J.T., Hubbard R., Walker R., Yu O., Crane P.K., Larson E.B. Cumulative use of strong anticholinergics and incident dementia: a prospective cohortstudy. JAMA Intern. Med. 2015;175:401. Doi: 10.1001/jamainternmed.2014.7663.

35. Risacher S.L., McDonald B.C., Tallman E.F., West J.D., Farlow M.R., Unverzagt F.W., Gao S., Boustani M., Crane P.K., Petersen R.C., Jack C.R. Jr, Jagust W.J., Aisen P.S., Weiner M.W., Saykin A.J.; Alzheimer’s Disease Neuroimaging Initiative. Association Between Anticholinergic Medication Use and Cognition, Brain Metabolism, and Brain Atrophy in Cognitively Normal Older Adults. JAMA Neurol. 2016 Jun 1;73(6):721–732. Doi: 10.1001/jamaneurol.2016.0580.

36. Isik A.T., Celik T., Bozoglu E., Doruk H. Trospium and cognition in patients with late onset Alzheimer disease. J. Nutr. Health Aging. 2009;13: 672. Doi: 10.1007/s12603-009-0196-5.

37. Sand P.K., Johnson Ii. T.M., Rovner E.S., Ellsworth P.I., Oefelein M.G., Staskin D.R. Trospium chloride once-daily extended release is efficacious and tolerated in elderly subjects (aged ≥ 75 years) with overactive bladder syndrome. BJU Int. 2011 Feb;107(4):612–620. Doi: 10.1111/j.1464-410X.2010.09519.x.

38. Kessler T.M., Bachmann L.M., Minder C., Löhrer D., Umbehr M., Schünemann H.J., Kessels A.G. Adverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approach. PLoS One. 2011 Feb 23;6(2):e16718. Doi: 10.1371/journal.pone.0016718.

39. Paquette A., Gou P., Tannenbaum C. Systematic review and meta-analysis: do clinical trials testing antimuscarinic agents for overactive bladder adequately measure central nervous system adverse events? J. Am. Geriatr. Soc. 2011 Jul;59(7):1332–1339. Doi: 10.1111/j.1532-5415.2011.03473.x.

40. Kay G., Crook T., Rekeda L., Lima R., Ebinger U., Arguinzoniz M,. Steel M. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects. Eur. Urol. 2006 Aug;50(2):317–326. Doi: 10.1016/j.eururo.2006.03.057.

41. Dawood O., El-Zawahry A. Mirabegron. Treasure Island (FL): StatPearls Publishing; 2021 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538513.

42. Chapple C.R., Cardozo L., Nitti V.W., Siddiqui E., Michel M.C. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014 Jan;33(1):17–30. Doi: 10.1002/nau.22505.

43. Khullar V., Amarenco G., Angulo J., Cambronero J., Høye K., Milsom I., et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur. Urol. 2013:63: 283–295. Doi: 10.1016/j.eururo.2012.10.016.

44. Wagg A., Staskin D., Engel E., Herschorn S., Kristy R.M., Schermer C.R. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Eur. Urol. 2020 Feb;77(2):211–220. Doi: 10.1016/j.eururo.2019.10.002.

45. Griebling T.L., Campbell N.L., Mangel J., Staskin D., Herschorn S., Elsouda D., Schermer C.R. Effect of mirabegron on cognitive function in elderly patients with overactive bladder: MoCA results from a phase 4 randomized, placebo-controlled study (PILLAR). BMC Geriatr. 2020 Mar;20(1):109. Doi: 10.1186/s12877-020-1474-7.

46. Welk B., McArthur E. Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study. BJU Int. 2020 Jul;126(1):183–190. Doi: 10.1111/bju.15040.

47. Nakagomi H., Mitsui T., Shimura H., Ihara T., Kira S., Sawada N., Takeda M. Mirabegron for overactive bladder in frail patients 80 years or over (HOKUTO study). BMC Urol. 2022 Mar;22(1):40. Doi: 10.1186/s12894-022-00989-7.

48. Veeratterapillay R., Harding C., Teo L., Vasdev N., Abroaf A., Dorkin T.J., Pickard R.S., Hasan T., Thorpe A.C. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity. Int. J. Urol. 2014 Feb;21(2):175–178. Doi: 10.1111/iju.12205.

49. Mohee A., Khan A., Harris N., Eardley I. Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB). BJU Int. 2013 Jan;111(1):106–113. Doi: 10.1111/j.1464-410X.2012.11282.x.

50. Nitti V.W., Dmochowski R., Herschorn S., Sand P., Thompson C., Nardo C., Yan X., Haag-Molkenteller C. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: Results of a phase 3, randomized, placebo-controlled trial. J. Urol. 2013;189:2186–2193. Doi: 10.1016/j.juro.2012.12.022.

51. Chapple C., Sievert K.D., MacDiarmid S., Khullar V., Radziszewski P., Nardo C., Thompson C., Zhou J., Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: A randomised, double-blind, placebo-controlled trial. Eur. Urol. 2013;64:249–256. Doi: 10.1016/j.eururo.2013.04.001.

52. Liao C.H., Chen S.F., Kuo H.C. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study. Neurourol. Urodyn. 2016;35:717–723. Doi: 10.1002/nau.22780.

53. Liao C.H., Kuo H.C. Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxin A injection for refractory idiopathic detrusor overactivity. J. Urol. 2013;189:1804–1810. Doi: 10.1016/j.juro.2012.11.089.

54. Kuo H.C., Liao C.H., Chung S.D. Adverse events of intravesical botulinum toxin a injections for idiopathic detrusor overactivity: Risk factors and influence on treatment outcome. Eur. Urol. 2010;58:919–926. Doi: 10.1016/j.eururo.2010.09.007.

55. Yokoyama O., Honda M., Yamanishi T., Sekiguchi Y., Fujii K., Nakayama T., Mogi T. OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: Results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis) Int. J. Urol. Off. J. Jpn. Urol. Assoc. 2020;27:227–234. Doi: 10.1111/iju.14176.

56. Miotla P., Cartwright R., Skorupska K., Bogusiewicz M., Markut-Miotla E., Futyma K., Rechberger T. Urinary retention in female OAB after intravesical Botox injection: Who is really at risk? Int. Urogynecol. J. 2017;28:845–850. Doi: 10.1007/s00192-016-3212-4.

57. Ou Y.C., Kao Y.L., Ho Y.H., Wu K.Y., Kuo H.C. Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder-Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes. Toxins (Basel). 2023 Jan;15(2):95. Doi: 10.3390/toxins15020095.

58. McGuire E.J., Zhang S.C., Horwinski E.R., Lytton B. Treatment of motor and sensory detrusor instability by electrical stimulation. J. Urol. 1983 Jan;129(1):78–79. Doi: 10.1016/s0022-5347(17)51928-x.

59. Chang P.L. Urodynamic studies in acupuncture for women with frequency, urgency and dysuria. J. Urol. 1988 Sep;140(3):563–566. Doi: 10.1016/s0022-5347(17)41719-8.

60. Stoller M.L. Percutaneous neuromodulation. Urol. Clin. North Am. 2005 Feb;32(1):71–78, vii. Doi: 10.1016/j.ucl.2004.09.007.

61. Zomkowski K., Kammers I., Back B.B.H., Moreira G.M., Sonza A., Sacomori C., Sperandio F.F. The effectiveness of different electrical nerve stimulation protocols for treating adults with non-neurogenic overactive bladder: a systematic review and meta-analysis. Int. Urogynecol. J. 2022 May;33(5):1045–1058. Doi: 10.1007/s00192-022-05088-7.

62. Sonmez R.,Yildiz N., Alkan H. Efficacy of percutaneous and transcutaneous tibial nerve stimulation in women with idiopathic overactive bladder: A prospective randomised controlled trial. Ann. Phys. Rehabil. Med. 2022 Jan;65(1):101486. Doi: 10.1016/j.rehab.2021.101486.

63. Wang M., Jian Z., Ma Y., Jin X., Li H., Wang K. Percutaneous tibial nerve stimulation for overactive bladder syndrome: a systematic review and meta-analysis. Int. Urogynecol. J. 2020;31(12):2457–2471. Doi: 10.1007/s00192-020-04429-8.

64. Palmer C., Nguyen N., Ghoniem G. Clinical outcomes of percutaneous tibial nerve stimulation in elderly patients with overactive bladder. Arab. J. Urol. 2019;17(1):10–13. Doi: 10.1080/2090598X.2019.1590032.

65. Suskind A.M., Clemens J.Q., Zhang Y., Hollenbeck B.K. Physician use of sacral neuromodulation among medicare beneficiaries with overactive bladder and urinary retention. Urology. 2015;86(1):30–34. Doi: 10.1016/j.urology.2015.04.003

66. Laudano M.A., Seklehner S., Sandhu J., et al. Disparities in the use of sacral neuromodulation among medicare beneficiaries. J. Urol. 2015;194(2):449–453. Doi: 10.1016/j.juro.2015.03.111

67. Greenberg D.R., Raveen S., Young-Lin N., Comiter C.V., Enemchukwu E. Outcomes of sacral nerve stimulation for treatment of refractory overactive bladder among octogenarians. Neuromodulation. 2019;22(6):738–744. Doi: 10.1111/ner.12981

68. Schönburg S., Bukethal T., Fornara P. Does age alone negatively predict the outcome of sacral neuromodulation? A single-centre retrospective observational study. BMC Urol. 2020;20(1):55. Doi: 10.1186/s12894-020-00621-6

69. Faris A.E.R., Gill B.C., Pizarro-Berdichevsky J., et al. Impact of age and comorbidities on use of sacral neuromodulation. J. Urol. 2017;198(1):161–166. Doi: 10.1016/j.juro.2017.02.

70. Peters K.M., Killinger K.A., Gilleran J., Boura J.A. Does patient age impact outcomes of neuromodulation? Neurourol. Urodyn. 2013;32(1):30–36. Doi: 10.1002/nau.22268.

71. Dobberfuhl A.D., Mahal A., Dallas K.B., Choi K.M., Comiter C.V., Elliott C.S. Statewide success of staged sacral neuromodulation for the treatment of urinary complaints in California (2005–2011). Female Pelvic Med. Reconstr. Surg. 2020;26(7):437–442. Doi: 10.1097/SPV.0000000000000605.